| Literature DB >> 24616541 |
Crystal S Denlinger, Robert W Carlson, Madhuri Are, K Scott Baker, Elizabeth Davis, Stephen B Edge, Debra L Friedman, Mindy Goldman, Lee Jones, Allison King, Elizabeth Kvale, Terry S Langbaum, Jennifer A Ligibel, Mary S McCabe, Kevin T McVary, Michelle Melisko, Jose G Montoya, Kathi Mooney, Mary Ann Morgan, Tracey O'Connor, Electra D Paskett, Muhammad Raza, Karen L Syrjala, Susan G Urba, Mark T Wakabayashi, Phyllis Zee, Nicole McMillian, Deborah Freedman-Cass.
Abstract
Various anticancer treatments, especially those directed toward the pelvis, can damage blood vessels and reduce circulation of blood to the penis and/or damage the autonomic nervous system, resulting in higher rates of erectile dysfunction in survivors than in the general population. In addition, hormonal therapy can contribute to sexual problems, as can depression and anxiety, which are common in cancer survivors. This section of the NCCN Guidelines for Survivorship provides screening, evaluation, and treatment recommendations for male sexual problems, namely erectile dysfunction.Entities:
Mesh：
Year: 2014 PMID： 24616541 PMCID： PMC4465261 DOI： 10.6004/jnccn.2014.0037
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908